US · HELP
Cybin Inc. Common Stock
- Sector
- Healthcare · Biotechnology
- Headquarters
- Toronto, ON M5X 1C9
- Website
- cybin.com
Price · as of 2025-03-31
$5.15
Market cap 366.72M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $49.99 | ||||
| 2020 | $19.89 | ||||
| 2021 | $58.14 | ||||
| 2022 | $25.46 | $33.96 | |||
| 2023 | $9.20 | ||||
| 2024 | $11.02 | ||||
| 2025 | $8.90 |
AI valuation
Our deep-learning model estimates Cybin Inc. Common Stock's (HELP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.15
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HELP | Cybin Inc. Common Stock | $5.15 | 366.72M | — | — | — | — | -2.22 | 1.06 | — | -0.82 | — | 1.74 | 0.00% | — | — | -42.76% | -154.42% | -40.36% | 0.00 | — | 7.75 | 6.58 | 0.95 | -9352.00% | — | 4833.00% | -41.06% | -4.73 | -111.40% | 0.00% | 0.00% | 0.00% | -0.81 | -1.13 | — | 4.05 |
About Cybin Inc. Common Stock
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
- CEO
- Michael F. Cola
- Employees
- 50
- Beta
- 0.85
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.15) − 1 = — (DCF, example).